Drug Trial Radar · NCT03414008
This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
54
Actual
Start
Feb 5, 2018
Primary completion
Nov 18, 2019
Study completion Nov 18, 2019
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to investigate the safety and tolerability of BI 1291583 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality and pharmacodynamics (PD) of BI 1291583 after single dosing.
Conditions
- Healthy
Interventions
BI 1291583Drug
Single dose
Matching placebo: Tartaric acidDrug
Single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess safety and tolerability of BI 1291583 is the number [N (%)] of subjects with drug-related adverse eventsTime frame: up to 120 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.